Bull Case
STRO-004 has produced early clinical responses in heavily pretreated patients, with rapid enrollment, mostly low-grade adverse events, predictable PK, and only 6% discontinuation due to adverse events. STRO-006 and partnered Astellas programs add pipeline optionality, while management reported $164.3 million of cash, cash equivalents, and marketable securities expected to fund operations into at least Q2 2028 [#SEC-8K-2026-08-12].
Bear Case
The lead asset remains in dose escalation with no defined maximum tolerated dose; dose-limiting toxicities occurred at 5 mg/kg, dose reduction was required, and reported responses include unconfirmed partial responses. The deterministic prior remains negative, with estimated returns of -8.6% over 20 days and -18.1% over 120 days. Clinical efficacy, durability, and registration potential remain unproven.
